-

SHAREHOLDER ALERT: Robbins LLP Investigates Natera, Inc. (NTRA) on Behalf of Shareholders

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP is investigating Natera, Inc. (NASDAQ: NTRA) to determine whether certain Natera officers and directors violated securities laws and breached fiduciary duties to shareholders. Natera develops and commercializes molecular testing, including a non-invasive prenatal test that screens for chromosomal abnormalities.

If you would like more information about our investigation of Natera, Inc.'s misconduct, click here.

Natera, Inc.'s (NTRA) Prenatal Tests May be Inaccurate

On January 1, 2022, an article from the New York Times called into question the accuracy of certain noninvasive prenatal tests, including that developed by Natera. The article alleges that positive results on tests are incorrect about 85% percent of the time. Patients who receive a positive result are supposed to pursue follow-up testing, which are expensive, invasive and cannot be performed until later in pregnancy. The investigation highlights the statistical challenge of testing from things that are extremely rare. But, this isn't adequately explained to patients who were sold the tests. Companies that develop these tests use language like "highly accurate" and "total confidence," do not publish data on their tests' overall performance, or only stress data from tests that are more accurate.

On this news, Natera's stock declined as much as 3.5% during intraday trading on January 3, 2022, injuring investors.

Natera, Inc. (NTRA) shareholders have legal options. If you own shares of Natera, Inc. contact us for more information about your legal options.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

Contact us to learn more:

Aaron Dumas
(800) 350-6003
adumas@robbinsllp.com
Shareholder Information Form

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against Natera, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Aaron Dumas
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Robbins LLP Urges GOSS Stockholders to Contact the Firm for Information About the Class Action Against Gossamer Bio, Inc.

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Gossamer Bio, Inc. (NASDAQ: GOSS) securities between June 16, 2025 and February 20, 2026. Gossamer is a clinical stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary hypertension (PH) associated with interstitial lung disease.For more information, submit a form, email att...

Robbins LLP Urges IBRX Stockholders to Contact the Firm for Information About the Class Action Against ImmunityBio, Inc.

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired ImmunityBio, Inc. (NASDAQ: IBRX) securities between January 19, 2026 and March 25, 2026. ImmunityBio is a biotechnology company and ANKTIVA is the Company's lead biologic product. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. What is the class period? January 19, 2026 – March 25, 202...

Robbins LLP Reminds ALDX Investors of the Pending Class Action Lawsuit; Harmed Investors Should Contact the Firm for Information About Leading the Case Against Aldeyra Therapeutics, Inc.

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) securities between November 3, 2023 and March 16, 2026. Defendant Aldeyra describes itself as a “biotechnology company devoted to discovering innovative therapies designed to treat immune-mediated diseases.” Pertinent to this action is reproxalap, which is a novel reactive aldehyde species (RASP) inhib...
Back to Newsroom